{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T07:42:57Z","timestamp":1792395777488,"version":"4.4.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","derm.theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.det.2015.11.002","type":"journal-article","created":{"date-parts":[[2016,3,23]],"date-time":"2016-03-23T01:34:58Z","timestamp":1458696898000},"page":"175-184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Oral Isotretinoin"],"prefix":"10.1016","volume":"34","author":[{"given":"Jerry","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanwarjit","family":"Boyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karishma","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Knezevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.det.2015.11.002_bib1","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1365-2133.2011.10686.x","article-title":"Oral isotretinoin and pregnancy prevention programmes","volume":"166","author":"Thiboutot","year":"2012","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2015.11.002_bib2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s40257-013-0014-z","article-title":"Important controversies associated with isotretinoin therapy for acne","volume":"14","author":"Wolverton","year":"2013","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"10.1016\/j.det.2015.11.002_bib3","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/j.1365-2133.2010.09836.x","article-title":"Advice on the safe introduction and continued use of isotretinoin in acne in the U.K. 2010","volume":"162","author":"Goodfield","year":"2010","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2015.11.002_bib4","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/ajd.12117","article-title":"Isotretinoin and mental health in adolescents: Australian consensus","volume":"55","author":"Rowe","year":"2013","journal-title":"Australas J Dermatol"},{"issue":"Suppl 1","key":"10.1016\/j.det.2015.11.002_bib5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/bjd.13639","article-title":"Management of severe acne","volume":"172","author":"Zouboulis","year":"2015","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.det.2015.11.002_bib6","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/dth.12084","article-title":"Isotretinoin updates","volume":"26","author":"On","year":"2013","journal-title":"Dermatol Ther"},{"issue":"3","key":"10.1016\/j.det.2015.11.002_bib7","doi-asserted-by":"crossref","first-page":"162","DOI":"10.4161\/derm.1.3.9364","article-title":"The use of isotretinoin in acne","volume":"1","author":"Layton","year":"2009","journal-title":"Dermatoendocrinol"},{"issue":"10","key":"10.1016\/j.det.2015.11.002_bib8","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1038\/sj.jid.5700289","article-title":"13-cis retinoic acid induces apoptosis and cell cycle arrest in human SEB-1 sebocytes","volume":"126","author":"Nelson","year":"2006","journal-title":"J\u00a0Invest Dermatol"},{"issue":"3","key":"10.1016\/j.det.2015.11.002_bib9","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1365-2133.2011.10392.x","article-title":"TRAIL contributes to the apoptotic effect of 13-cis retinoic acid in human sebaceous gland cells","volume":"165","author":"Nelson","year":"2011","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.det.2015.11.002_bib10","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1172\/JCI33869","article-title":"Neutrophil gelatinase\u2013associated lipocalin mediates 13-cis retinoic acid\u2013induced apoptosis of human sebaceous gland cells","volume":"118","author":"Nelson","year":"2008","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"10.1016\/j.det.2015.11.002_bib11","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1365-2133.2011.10362.x","article-title":"Isotretinoin increases skin-surface levels of neutrophil gelatinase-associated lipocalin in patients treated for severe acne","volume":"165","author":"Lumsden","year":"2011","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.det.2015.11.002_bib12","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1038\/jid.2012.111","article-title":"Systemic isotretinoin therapy normalizes exaggerated TLR-2-mediated innate immune responses in acne patients","volume":"132","author":"Dispenza","year":"2012","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.det.2015.11.002_bib13","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000375370","article-title":"The effect of different doses of isotretinoin on pituitary hormones","volume":"230","author":"Karadag","year":"2015","journal-title":"Dermatology"},{"key":"10.1016\/j.det.2015.11.002_bib14","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER). Guidance for industry: food-effect bioavailability and fed bioequivalence studies. 2002:1\u201312. Available at: http:\/\/www.fda.gov\/downloads\/RegulatoryInformation\/Guidances\/UCM126833.pdf."},{"issue":"11\u201312","key":"10.1016\/j.det.2015.11.002_bib15","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/j.1552-4604.1983.tb01800.x","article-title":"Food increases the bioavailability of isotretinoin","volume":"23","author":"Colburn","year":"1983","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.det.2015.11.002_bib16","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.jada.2010.03.023","article-title":"The relationship of breakfast skipping and type of breakfast consumption with nutrient intake and weight status in children and adolescents: the National Health and Nutrition Examination Survey 1999-2006","volume":"110","author":"Deshmukh-Taskar","year":"2010","journal-title":"J\u00a0Am Diet Assoc"},{"issue":"2 Suppl","key":"10.1016\/j.det.2015.11.002_bib17","first-page":"S3","article-title":"The use of isotretinoin in the treatment of acne vulgaris: clinical considerations and future directions","volume":"7","author":"Leyden","year":"2014","journal-title":"J\u00a0Clin Aesthet Dermatol"},{"issue":"1","key":"10.1016\/j.det.2015.11.002_bib18","doi-asserted-by":"crossref","first-page":"12","DOI":"10.5070\/D39VX5D02Z","article-title":"Are we underdosing acne patients with generic isotretinoin?","volume":"19","author":"Mutizwa","year":"2013","journal-title":"Dermatol Online J"},{"issue":"6","key":"10.1016\/j.det.2015.11.002_bib19","first-page":"665","article-title":"Results of a phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne","volume":"13","author":"Webster","year":"2014","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"6","key":"10.1016\/j.det.2015.11.002_bib20","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1111\/bjd.13191","article-title":"A\u00a0treatment for severe nodular acne: a randomized investigator-blinded, controlled, noninferiority trial comparing fixed-dose adapalene\/benzoyl peroxide plus doxycycline vs. oral isotretinoin","volume":"171","author":"Tan","year":"2014","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.det.2015.11.002_bib21","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1365-4632.2011.05409.x","article-title":"High-dose isotretinoin in acne vulgaris: improved treatment outcomes and quality of life","volume":"51","author":"Cyrulnik","year":"2012","journal-title":"Int J Dermatol"},{"issue":"12","key":"10.1016\/j.det.2015.11.002_bib22","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1001\/jamadermatol.2013.6746","article-title":"High-dose isotretinoin treatment and the rate of retrial, relapse, and adverse effects in patients with acne vulgaris","volume":"149","author":"Blasiak","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.det.2015.11.002_bib23","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/j.1365-2133.2010.10152.x","article-title":"Effectiveness of conventional, low-dose and intermittent oral isotretinoin in the treatment of acne: a randomized, controlled comparative study","volume":"164","author":"Lee","year":"2011","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2015.11.002_bib24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1440-0960.2012.00947.x","article-title":"Isotretinoin: dose, duration and relapse. What does 30 years of usage tell us?","volume":"54","author":"Rademaker","year":"2012","journal-title":"Australas J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2015.11.002_bib25","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/j.1365-2133.2011.10440.x","article-title":"Low-dose isotretinoin in acne vulgaris: a critical review","volume":"165","author":"Sardana","year":"2011","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.det.2015.11.002_bib26","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1440-0960.2010.00657.x","article-title":"Adverse effects of isotretinoin: a retrospective review of 1743 patients started on isotretinoin","volume":"51","author":"Rademaker","year":"2010","journal-title":"Australas J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2015.11.002_bib27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1440-0960.2011.00764.x","article-title":"On isotretinoin dosing, adverse effects, and efficacy","volume":"52","author":"Berk","year":"2011","journal-title":"Australas J Dermatol"},{"issue":"9","key":"10.1016\/j.det.2015.11.002_bib28","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/j.1468-3083.2010.03933.x","article-title":"Low-cumulative dose isotretinoin treatment in mild-to-moderate acne: efficacy in achieving stable remission","volume":"25","author":"Borghi","year":"2011","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.det.2015.11.002_bib29","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/jdv.12170","article-title":"Isotretinoin 5 mg daily for low-grade adult acne vulgaris - a placebo-controlled, randomized double-blind study","volume":"28","author":"Rademaker","year":"2014","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"6 Pt 2","key":"10.1016\/j.det.2015.11.002_bib30","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0190-9622(08)80252-6","article-title":"Guidelines for optimal use of isotretinoin in acne","volume":"27","author":"Layton","year":"1992","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2015.11.002_bib31","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1159\/000246134","article-title":"Roaccutane treatment guidelines: results of an international survey","volume":"194","author":"Cunliffe","year":"1997","journal-title":"Dermatology"},{"key":"10.1016\/j.det.2015.11.002_bib32","first-page":"46","article-title":"On Dosage and Diet: Isotretinoin 101","author":"Zeichner","year":"2014","journal-title":"Pract Dermatol"},{"issue":"11","key":"10.1016\/j.det.2015.11.002_bib33","first-page":"17","article-title":"Face to face with oral isotretinoin: a closer look at the spectrum of therapeutic outcomes and why some patients need repeated courses","volume":"5","author":"Del Rosso","year":"2012","journal-title":"J\u00a0Clin Aesthet Dermatol"},{"issue":"4","key":"10.1016\/j.det.2015.11.002_bib34","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jaad.2006.08.048","article-title":"Guidelines of care for acne vulgaris management","volume":"56","author":"Strauss","year":"2007","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.11.002_bib35","unstructured":"Malaysia Ministry of Health, Dermatological Society of Malaysia, Academy of Medicine Malaysia. Clinical practice guidelines: management of acne. 2012. Available at: http:\/\/www.moh.gov.my. Accessed July 15, 2012."},{"key":"10.1016\/j.det.2015.11.002_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3083.2011.04374.x","article-title":"European evidence-based (S3) guidelines for the treatment of acne","volume":"26","author":"Nast","year":"2012","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.det.2015.11.002_bib37","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/j.1365-2133.2007.08250.x","article-title":"Isotretinoin therapy and the incidence of acne relapse: a nested case-control study","volume":"157","author":"Azoulay","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2015.11.002_bib38","article-title":"Evaluation of evidence for acne remission with oral isotretinoin cumulative dosing of 120-150 mg\/kg","author":"Tan","year":"2015","journal-title":"J Cutan Med Surg"},{"issue":"10","key":"10.1016\/j.det.2015.11.002_bib39","doi-asserted-by":"crossref","first-page":"896","DOI":"10.3109\/15563650.2012.739287","article-title":"Pregnancy outcomes and factors associated with voluntary pregnancy termination in women who had been treated for acne with isotretinoin","volume":"50","author":"Yook","year":"2012","journal-title":"Clin Toxicol"},{"issue":"11","key":"10.1016\/j.det.2015.11.002_bib40","doi-asserted-by":"crossref","first-page":"e005602","DOI":"10.1136\/bmjopen-2014-005602","article-title":"Isotretinoin exposure during pregnancy: a population-based study in The Netherlands","volume":"4","author":"Zomerdijk","year":"2014","journal-title":"BMJ Open"},{"issue":"12","key":"10.1016\/j.det.2015.11.002_bib41","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/pds.3481","article-title":"Concomitant use of isotretinoin and contraceptives before and after iPledge in the United States","volume":"22","author":"Pinheiro","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.det.2015.11.002_bib42","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaad.2013.08.034","article-title":"Compliance with pregnancy prevention measures during isotretinoin therapy","volume":"70","author":"Collins","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2015.11.002_bib43","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1001\/jamadermatol.2013.6862","article-title":"Women\u2019s experiences with isotretinoin risk reduction counseling","volume":"150","author":"Werner","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.det.2015.11.002_bib44","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.clindermatol.2014.05.002","article-title":"Contraceptive use in acne","volume":"32","author":"Lam","year":"2014","journal-title":"Clin Dermatol"},{"issue":"4","key":"10.1016\/j.det.2015.11.002_bib45","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jaad.2012.09.023","article-title":"Isotretinoin and affective disorders: thirty years later","volume":"68","author":"Thiboutot","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.11.002_bib46","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1744-859X-8-2","article-title":"Isotretinoin and psychopathology: a review","volume":"8","author":"Kontaxakis","year":"2009","journal-title":"Ann Gen Psychiatry"},{"issue":"2","key":"10.1016\/j.det.2015.11.002_bib47","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/jid.2010.375","article-title":"Consequences of psychological distress in adolescents with acne","volume":"131","author":"Misery","year":"2010","journal-title":"J\u00a0Invest Dermatol"},{"issue":"9","key":"10.1016\/j.det.2015.11.002_bib48","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/ijd.12169","article-title":"Does isotretinoin therapy of acne cure or cause depression?","volume":"52","author":"Borovaya","year":"2013","journal-title":"Int J Dermatol"},{"issue":"4","key":"10.1016\/j.det.2015.11.002_bib49","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1365-4632.2011.05182.x","article-title":"Association between isotretinoin and mood changes: myth or reality? An updated overview","volume":"52","author":"D\u2019Erme","year":"2011","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.det.2015.11.002_bib50","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4088\/JCP.10r05993","article-title":"Retinoic acid and affective disorders: the evidence for an association","volume":"73","author":"Bremner","year":"2012","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.det.2015.11.002_bib51","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1067\/mjd.2001.115966","article-title":"Safety of a\u00a0new micronized formulation of isotretinoin in patients with severe recalcitrant nodular acne: a randomized trial comparing micronized isotretinoin with standard isotretinoin","volume":"45","author":"Strauss","year":"2001","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.11.002_bib52","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/S0190-9622(08)81018-3","article-title":"Acute depression from isotretinoin","volume":"22","author":"Scheinman","year":"1990","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.11.002_bib53","doi-asserted-by":"crossref","first-page":"526","DOI":"10.4088\/JCP.v69n0403","article-title":"Isotretinoin and the risk of depression in patients with acne vulgaris: a case-crossover study","volume":"69","author":"Azoulay","year":"2008","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.det.2015.11.002_bib54","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1037\/0021-843X.102.1.133","article-title":"Adolescent psychopathology: I. Prevalence and incidence of depression and other DSM-III-R disorders in high\u00a0school students","volume":"102","author":"Lewinsohn","year":"1993","journal-title":"J\u00a0Abnorm Psychol"},{"issue":"2","key":"10.1016\/j.det.2015.11.002_bib55","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/jid.2010.264","article-title":"Suicidal ideation, mental health problems, and social impairment are increased in adolescents with acne: a population-based study","volume":"131","author":"Halvorsen","year":"2011","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.det.2015.11.002_bib56","doi-asserted-by":"crossref","first-page":"c5812","DOI":"10.1136\/bmj.c5812","article-title":"Association of suicide attempts with acne and treatment with isotretinoin: retrospective Swedish cohort study","volume":"341","author":"Sundstr\u00f6m","year":"2010","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.det.2015.11.002_bib57","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jpsychores.2004.09.006","article-title":"Detecting and monitoring depression with a two-item questionnaire (PHQ-2)","volume":"58","author":"L\u00f6we","year":"2005","journal-title":"J\u00a0Psychosom Res"},{"issue":"11","key":"10.1016\/j.det.2015.11.002_bib58","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1097\/01.MLR.0000093487.78664.3C","article-title":"The patient health questionnaire-2: validity of a two-item depression screener","volume":"41","author":"Kroenke","year":"2003","journal-title":"Med Care"},{"issue":"11","key":"10.1016\/j.det.2015.11.002_bib59","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1007\/s11606-007-0333-y","article-title":"Screening for depression in medical settings with the Patient Health Questionnaire (PHQ): a diagnostic meta-analysis","volume":"22","author":"Gilbody","year":"2007","journal-title":"J\u00a0Gen Intern Med"},{"issue":"12","key":"10.1016\/j.det.2015.11.002_bib60","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1176\/appi.ajp.161.12.2163","article-title":"The Hamilton Depression Rating Scale: has the gold standard become a lead weight?","volume":"161","author":"Bagby","year":"2004","journal-title":"Am J Psychiatry"},{"issue":"2","key":"10.1016\/j.det.2015.11.002_bib61","first-page":"244","article-title":"Screening instruments for depression","volume":"78","author":"Ebell","year":"2008","journal-title":"Am Fam Physician"},{"issue":"11","key":"10.1016\/j.det.2015.11.002_bib62","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1038\/ajg.2009.417","article-title":"Isotretinoin is not associated with inflammatory bowel disease: a population-based case-control study","volume":"104","author":"Bernstein","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.det.2015.11.002_bib63","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/ajg.2010.124","article-title":"Isotretinoin use and the risk of inflammatory bowel disease: a case-control study","volume":"105","author":"Crockett","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.det.2015.11.002_bib64","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1001\/jamadermatol.2013.1344","article-title":"Isotretinoin and risk for inflammatory bowel disease: a nested case-control study and meta-analysis of published and unpublished data","volume":"149","author":"Etminan","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.det.2015.11.002_bib65","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/jid.2012.387","article-title":"Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study","volume":"133","author":"Alhusayen","year":"2013","journal-title":"J\u00a0Invest Dermatol"},{"issue":"4","key":"10.1016\/j.det.2015.11.002_bib66","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/ajg.2014.8","article-title":"Isotretinoin and risk of inflammatory bowel disease: a French nationwide study","volume":"109","author":"Racine","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"10.1016\/j.det.2015.11.002_bib67","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1001\/jamadermatol.2014.1540","article-title":"Isotretinoin exposure and risk of inflammatory bowel disease","volume":"150","author":"Rashtak","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"11","key":"10.1016\/j.det.2015.11.002_bib68","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1038\/ajg.2014.246","article-title":"Antibiotics associated with increased risk of new-onset Crohn's disease but not ulcerative colitis: a meta-analysis","volume":"109","author":"Ungaro","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"2 Pt 1","key":"10.1016\/j.det.2015.11.002_bib69","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0190-9622(86)70167-9","article-title":"Atypical keloids after dermabrasion of patients taking isotretinoin","volume":"15","author":"Rubenstein","year":"1986","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5 Pt 2","key":"10.1016\/j.det.2015.11.002_bib70","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S0190-9622(94)70096-6","article-title":"Atypical facial scarring after isotretinoin therapy in a patient with previous dermabrasion","volume":"30","author":"Katz","year":"1994","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.det.2015.11.002_bib71","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1365-2133.1988.tb02574.x","article-title":"Delayed wound healing and keloid formation following argon laser treatment or dermabrasion during isotretinoin treatment","volume":"118","author":"Zachariae","year":"1988","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.det.2015.11.002_bib72","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/j.1524-4725.2012.02460.x","article-title":"Early chemabrasion for acne scars after treatment with oral isotretinoin","volume":"38","author":"Picosse","year":"2012","journal-title":"Dermatol Surg"},{"issue":"4","key":"10.1016\/j.det.2015.11.002_bib73","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1524-4725.2010.01474.x","article-title":"Dermabrasion for acne scars during treatment with oral isotretinoin","volume":"36","author":"Bagatin","year":"2010","journal-title":"Dermatol Surg"},{"issue":"12","key":"10.1016\/j.det.2015.11.002_bib74","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1097\/DSS.0000000000000185","article-title":"The safe delivery of fractional ablative carbon dioxide laser treatment for acne scars in Asian patients receiving oral isotretinoin","volume":"40","author":"Kim","year":"2014","journal-title":"Dermatol Surg"},{"issue":"2","key":"10.1016\/j.det.2015.11.002_bib75","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3109\/09546634.2013.768758","article-title":"Concomitant use of an infrared fractional laser with low-dose isotretinoin for the treatment of acne and acne scars","volume":"25","author":"Yoon","year":"2014","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.det.2015.11.002_bib76","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/j.1524-4725.1990.tb00026.x","article-title":"Systemic isotretinoin: effects on dermal wound healing in a rabbit ear model in\u00a0vivo","volume":"16","author":"Moy","year":"1990","journal-title":"J\u00a0Dermatol Surg Oncol"},{"issue":"8","key":"10.1016\/j.det.2015.11.002_bib77","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1177\/1090820X12462383","article-title":"Does systemic isotretinoin inhibit healing in a porcine wound model?","volume":"32","author":"Larson","year":"2012","journal-title":"Aesthet Surg J"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863515001412?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863515001412?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T09:37:08Z","timestamp":1692265028000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863515001412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":77,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0733863515001412"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2015.11.002","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral Isotretinoin","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2015.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}